All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Frontline quadruplet therapy for multiple myeloma: Update from SOHO 2024
Bookmark this article
|
Quadruplet therapies combining anti-CD38 monoclonal antibodies, a proteasome inhibitor, an immunomodulatory agent, and dexamethasone in sequence with ASCT lead to deep and durable responses in NDMM.1 A review of outcomes in patients treated with upfront quadruplet therapies was presented at the Society of Hematologic Oncology (SOHO) 2024 Annual Meeting by Ajay Nooka.1
|
| Key learnings: |
|
The phase III PERSEUS (NCT03710603) trial demonstrated deep and durable responses with daratumumab + VRd compared with VRd in patients with transplant-eligible NDMM. |
|
Real-world findings and long-term results from the CASSIOPEIA trials confirmed the benefit of daratumumab-based quadruplet therapies in NDMM. |
|
Isatuximab + VRd demonstrated improved post-induction MRD negativity compared with VRd in the GMMG-HG7 (NCT03617731) trial. |
|
The phase III IMROZ (NCT03319667) and BENEFIT (NCT04751877) trials demonstrated that quadruplet therapies can improve the depth of response and lead to high rates of MRD negativity. This translated into a 63% 5-year PFS benefit for isatuximab + VRd vs VRd in the IMROZ study. |
|
Benefits of upfront quadruplet therapies in high-risk disease were demonstrated in the MASTER (NCT03224507) and GMMG-CONCEPT (NCT03104842) trials, and for transplant-ineligible elderly patients in the ALCYONE trial (NCT02195479). |
|
These findings suggest upfront quadruplet therapies as the preferred SoC for transplant-eligible and transplant-ineligible patients. The depth of response and high PFS rates offer the potential for improved disease control, delaying relapse. |
ASCT, autologous stem cell transplantation; MRD, measurable residual disease; NDMM, newly diagnosed multiple myeloma; PFS, progression-free survival; SoC, standard of care; VRd, bortezomib + lenalidomide + dexamethasone.
- Nooka A. Session VI: Multiple Myeloma. Frontline therapy – Quads for everyone? Society of Hematologic Oncology (SOHO) 2024 Annual Meeting; Sep 4-7, 2024; Houston, US.
Your opinion matters
3 votes - 34 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox